Currently, the IDO inhibitor epacadostat is also being tested in combination with anti-PD-1 (nivolumab; NCT02327078) and anti-PD-L1 (durvalumab; NCT02318277) for various cancers in phase I/II studies. Here, PDCD1 is linked to cancer.